Preston K. Ratliff II is the Chair of the Firm’s Litigation practice in New York. Mr. Ratliff focuses his practice on complex, high-stakes litigation with an emphasis on patent litigation in the biotechnology, pharmaceutical, chemical, agricultural, and renewable fuel sectors. He has successfully represented major and emerging companies both pre-trial and at trial.  Chambers USA notes that Mr. Ratliff is “really outstanding and excels at all aspects of litigation. What stands out is that he is a brilliant strategist who sees the big picture and can anticipate risks that aren’t always necessarily apparent…he is a very calming and unflappable presence even in the most difficult and stressful situations.” 

Mr. Ratliff also has extensive experience counseling clients with respect to their IP portfolios and evaluating strategic licensing opportunities.  In addition, Mr. Ratliff is a frequent publisher in patent journals and an invited speaker at some of the most prestigious life sciences industry conferences.

• Chambers USA, Intellectual Property: Patent (2022-2023)
• IAM Patent 1000, Leading Patent Practitioner (2015-2023)
• In addition, IAM noted that he “has prevailed at trial for major companies in hard-fought battles”; as testament to his leadership qualities and outstanding legal dexterity, he assumed the chairmanship of the New York Litigation practice.
• LMG Life Sciences, Life Sciences Star. (2018-2022)
• Managing Intellectual Property, IP Stars. (2019-2023)
• Topped Law360’s “Legal Lions” list for his Federal Circuit victory securing patent exclusivity against multiple defendants concerning Sunovion’s billion-dollar blockbuster schizophrenia and bipolar drug, Latuda®
• Selected as one IAM Strategy 300’s “World’s Leading IP Strategists”
• Named a “Minority Powerbroker” by Law360
• Named one of Law360’s five “Rising Stars” for Intellectual Property

• American University Washington College of Law, J.D. (1999)
• Syracuse University, B.S. in Chemical Engineering and minor in German Language (1996)